# Transgenic Mouse and Embryonic Stem Cell Facility

> **NIH NIH P30** · UNIVERSITY OF CHICAGO · 2022 · $214,254

## Abstract

ABSTRACT 
The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) Transgenic Mouse/Embryonic 
Stem Cell Facility (TMESCF) provides comprehensive genetic engineering services to alter the genome of the 
laboratory mouse. UCCCC investigators develop and exploit a variety of different mouse models of cancer to 
understand the etiology, progression and treatment of cancer as a disease. These approaches are particularly 
important to increase our understanding of the role of the immune system in tumorigenesis, and to develop 
increased knowledge of the factors affecting tumor metastasis, as well as other aspects of cancer that are best 
modeled in the whole animal. The Facility provides specialized technology to generate genetically engineered 
mice through the microinjection of mouse embryos and through the use of gene targeting/editing in embryonic 
stem (ES) cells. With the advent of new genome editing approaches, the demand for these services is greater 
than ever. In particular, demand from our faculty for CRISPR/Cas9 genome editing and TARGATT site- 
directed transgenics has grown exponentially over the past few years following our successful introduction of 
these technologies in 2013. The Transgenic Mouse/Embryonic Stem Cell Facility allows our investigators to 
develop mouse models of cancer at the cutting-edge of technology, with CRISPR/Cas9, for example, allowing 
us to introduce tags, specific deletions/mutations, and other genetic changes more rapidly and on a broader 
scale than in the past. Having such a dedicated Facility also allows our investigators to remain competitive in 
this rapidly evolving field, obtain much valued advice on the types of models that can be developed, and learn 
from the various new and innovative approaches being tested in the TMESCF.

## Key facts

- **NIH application ID:** 10379985
- **Project number:** 5P30CA014599-47
- **Recipient organization:** UNIVERSITY OF CHICAGO
- **Principal Investigator:** KAY F MACLEOD
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $214,254
- **Award type:** 5
- **Project period:** 1997-09-01 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10379985

## Citation

> US National Institutes of Health, RePORTER application 10379985, Transgenic Mouse and Embryonic Stem Cell Facility (5P30CA014599-47). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10379985. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*